Adam Golden’s practice focuses on mergers and acquisitions, securities offerings, intellectual property licenses, joint ventures and other corporate partnering transactions. He has represented companies in the pharmaceutical and biotechnology, infrastructure, chemicals, consumer products, information technology, healthcare services, medical devices, defense, finance and alternative asset management industries. Mr. Golden’s clients range in size from multibillion-dollar global businesses to emerging-stage companies.
MEHRMr. Golden has substantial experience representing clients for whom intellectual property is a key asset. As a lawyer with a background in science, he brings an in-depth understanding of the technology involved in transactions for the benefit of his clients. A particular focus is in the area of life sciences, where he has broad experience in the full range of licensing and collaboration transactions common to this sector.
Mr. Golden has been recognized annually as a leading practitioner in Chambers USA: America’s Leading Lawyers for Business and Legal 500 US.
Representative Matters
Mergers and Acquisitions
- Representation of a major pharmaceutical company in its agreement to sell to an international specialty pharmaceutical company the global rights to manufacture, market and commercialize a medicine for dermatitis for an upfront payment of $420 million.
- Major international pharmaceutical company in the acquisition of a Phase II/III stage privately held biopharmaceutical company for up to $620 million.
- Sale of infrastructure engineering and design firm for $626 million.
- Sale by a specialty pharmaceutical company of its progesterone-related assets and shares of common stock to a global pharmaceutical company for up to $107.5 million plus royalties.
- International investment bank in the divestiture of a multibillion-dollar portfolio of residential mortgage backed securities.
- European chemicals company in the acquisition of its U.S. partner’s interest in two polymers joint ventures for $265 million.
- European biotechnology company in the acquisition of the Biologics division of a U.S. pharmaceutical company for $185 million.
- Bank group in connection with financing of $2.5 billion acquisition of aircraft leasing company.
- Timber asset manager in $1.7 billion acquisition bid for timberlands and related assets.
Securities Transactions
- Issuers and investors in numerous venture capital financing rounds.
- Public companies and investors in PIPE, registered direct and other follow-on equity offerings, including common and preferred stock, warrants and convertible debt.
- Strategic investors in minority equity investments in licensors and other collaboration partners.
Licenses and Other Collaborations
- Representation of a major pharmaceutical company in its agreement to sell to an international specialty pharmaceutical company the global rights to manufacture, market and commercialize a medicine for dermatitis for an upfront payment of $420 million.
- Research division of a major international pharmaceutical company in a license and co-development collaboration involving an oncology product candidate for $45 million up-front, plus up to $422 million in milestone payments, plus royalties.
- Major international pharmaceutical company in an out-license of a cancer treatment to a specialty pharmaceutical company for $185 million up-front, plus up to $123 million in milestones, plus royalties.
- Restructuring of a prior licensing arrangement granting a major pharmaceutical company exclusive U.S. and Canadian rights to an oral medication for schizophrenia, for $200 million up-front, plus up to $265 million in milestones, plus royalties.
- Consumer health division of a major international pharmaceutical company in the out-license of a late-stage osteoarthritis product to a specialty pharmaceutical company for $85 million up-front, plus milestones and royalties.
- Strategic alliance between the vaccines division of a major international pharmaceutical company and an Austrian biotech company for an up-front payment and equity investment totaling approximately $365 million.
- Early stage biopharmaceutical company in a license, development and commercialization collaboration with a major U.S.-based pharmaceutical company on a product for complications from cardiac surgery.
- Major international pharmaceutical company in a research collaboration and license with a specialty biopharmaceutical company with respect to the development of potential oncology products for up to $515 million plus royalties.
Joint Ventures
- International cosmetics company in a joint venture with a local distributor to sell cosmetics and related products in Portugal.
- Restructuring of agricultural sciences joint venture controlled by a division of a major pharmaceuticals and chemicals company.
- Consumer health division of a major international pharmaceutical company in a joint venture with a consumer products company to develop and commercialize functional foods.
- Europe-based defense contractor in a joint venture with a U.S. defense contractor to jointly acquire and operate a business engaged in the design and production of defense, training, transportation and energy systems.
- Representation of a U.S.-based media company in the formation of a joint venture with a Europe-based media company to form a global media and entertainment information company.
- European chemicals company in the formation of a joint venture with a U.S.-based chemicals company with respect to the parties’ respective polymer businesses.